DDX41+SETBP1 Deep Dive
Germline/somatic DDX41 co-occurrence with SETBP1 in myeloid neoplasms
DDX41+SETBP1 co-occurrence analysis across GENIE v19.0 patients with
myeloid or histiocytic cancer types.
DDX41 germline mutations define a distinct myeloid neoplasm subtype. This
page examines their overlap with SETBP1 somatic mutations in the context
of a five-driver mutation profile.
DDX41+SETBP1
2 patients
O/E=4.26, p=0.079
DDX41 Coverage
16 panels
3,224 patients covered (myeloid + histiocytic cohort)
BH q-value
0.649
Not significant after correction
Novel Variants
1
EZH2 V662A (0 PubMed hits); PTPN11 E76Q is recurrent (11 GENIE samples)
Five-Driver Context
Classifying EZH2 V662A as Likely Pathogenic (PP3_Strong on
6/7 concordant computational predictors; EVE dissents at
0.7825, Uncertain at its class25 calibration)
is a research classification; ClinVar lists the variant as a VUS.
The index patient carries four confirmed driver mutations plus EZH2 V662A.
The exact five-variant combination has no estimable population frequency. Zero in 8,655 patients bounds it below 1 in 2,889 (95%, exact binomial).
ClinGen Gene-Disease Validity
| Gene | Disease | Validity | Classification Date |
|---|---|---|---|
| DNMT3A | Tatton-Brown-Rahman overgrowth syndrome (germline) | Definitive | 2023-06-08 |
| IDH2 | Mitochondrial disease (germline) | Definitive | 2023-01-30 |
| SETBP1 | Schinzel-Giedion syndrome (germline) | Definitive | 2021-02-16 |
| PTPN11 | Noonan syndrome (germline) | Definitive | 2018-07-24 |
| EZH2 | Weaver syndrome (germline) | Definitive | 2022-08-03 |
| DDX41 | DDX41-related hematologic malignancy predisposition syndrome | Definitive | 2020-07-30 |
ClinGen's gene-disease validity file (downloaded 2 November 2026) has a
Definitive curation for all 6 genes, but only the DDX41 curation concerns
a myeloid condition (inherited predisposition). The other five are
germline developmental or metabolic syndromes. ClinGen has no gene-disease
validity curation of these genes for somatic AML or MDS, so this table
does not by itself establish myeloid driver status.
DDX41+SETBP1 Co-occurrence
DDX41 germline mutations
7
[7] C 2015
Inherited and Somatic Defects in DDX41 in Myeloid Neoplasms. Cancer Cell (2015)
6[6] H 2023
Germ line DDX41 mutations define a unique subtype of myeloid neoplasms. Blood (2023)
are
an active area of myeloid neoplasm research. DDX41-mutant MN defy
current prognostic schemes
8[8] C 2026
DDX41-mutant myeloid neoplasms defy current prognostic schemes and require a dedicated risk scoring system: a multicenter, retrospective study. Leukemia (2026)
. This analysis found 2 co-mutated
patients with SETBP1 mutations
2[2] H 2013
Somatic SETBP1 mutations in myeloid malignancies. Nat Genet (2013)
1[1] R 2013
Recurrent SETBP1 mutations in atypical chronic myeloid leukemia. Nat Genet (2013)
in GENIE v19.0
17[17] Consortium 2017
AACR Project GENIE: Powering Precision Medicine through an International Consortium. Cancer Discov (2017)
among 3,224 patients (one sample each, GENIE
myeloid and histiocytic cancer types) whose panel covered both genes
(16 panels). The
co-occurrence has O/E=4.26, Fisher's exact
p=0.079, BH-adjusted q=0.649. All patients are from UHN (Toronto),
both AML, and both share EZH2 as an additional co-mutated gene.
| Sample ID | Cancer Type | DDX41 Mutation | SETBP1 Mutation | Other Genes | Total Mutations |
|---|---|---|---|---|---|
| withheld (GENIE terms) | AML | p.G402W + p.M1? | p.G870S (SKI) | ASXL1/CBL/DNMT3A/EZH2/RUNX1 | 8 |
| withheld (GENIE terms) | AML | p.Q329Rfs*7 | p.N454D (non-SKI) | EZH2 | 3 |
Note: Both patients from University
Health Network (Toronto). Both AML. Both share EZH2 co-mutation.
PTPN11 E76Q Knowledge Gap
Semantic Scholar searches (6 queries: 4 patient variants, 1
co-occurrence and 1 quadruple-mutation query; EZH2 V662A was not
queried) returned 144 unique publications. Type 1 progression mutations (PTPN11, IDH2)
15
[15] H 2017
Dynamics of clonal evolution in myelodysplastic syndromes. Nat Genet (2017)
are key to clonal evolution. Yet
PTPN11 E76Q returned only 2 publications, the fewest of any
variant queried. By comparison, DNMT3A R882H returned 100 (the search
cap) and IDH2 R140Q returned 19. This variant is significantly understudied relative to its
clinical significance: E76Q is a recurrent activating mutation in the
SHP2 phosphatase domain, found in both de novo and therapy-related
myeloid neoplasms.
Patient 2642: Closest Match
Patient 2642 is from the Beat AML study (OHSU, Cancer Cell 2022; 903
patients, searched via cBioPortal), not from GENIE. This patient carries
IDH2 R140Q + SETBP1 G870S + PTPN11 N308S: the same IDH2 and SETBP1
variants as the index patient, but a different PTPN11 variant (N308S,
not E76Q) and no DNMT3A mutation. It is the only patient with IDH2,
PTPN11 and SETBP1 mutations together in the databases searched; GENIE
v19.0 17
[17] Consortium 2017
AACR Project GENIE: Powering Precision Medicine through an International Consortium. Cancer Discov (2017)
has 0 samples with this
combination, even at gene level. No patient in any database has all
four mutations. With EZH2 V662A classified Likely Pathogenic (research classification), the
gap widens further: no EZH2 mutation is listed in either of Patient
2642's whole-exome samples, making this closest match even less close
to the full quintuple profile. Clonal succession
15[15] H 2017
Dynamics of clonal evolution in myelodysplastic syndromes. Nat Genet (2017)
modeling and IPSS-M
13[13] E 2022
Molecular International Prognostic Scoring System for Myelodysplastic Syndromes. NEJM Evid (2022)
scoring would both be needed to
fully characterize this case.
| Property | Value |
|---|---|
| Patient ID | 2642 (Beat AML) |
| Matching mutations | IDH2 R140Q, SETBP1 G870S (exact); PTPN11 N308S (same gene, not E76Q) |
| Missing from quadruple | DNMT3A R882H, PTPN11 E76Q |
| Database | Beat AML (OHSU, Cancer Cell 2022) via cBioPortal; not in GENIE v19.0 |
| Denominator | 903 Beat AML patients |
| Frequency | 1 / 903 (0.11%), IDH2+PTPN11+SETBP1 at gene level |
Note on DDX41 Numbers
An earlier, superseded analysis (21 March 2026; 14,601 patients selected
by the words "leukemia" or "myeloid" in the cancer type, which also took
in lymphoid leukemias; 271 SETBP1 patients) found 3 co-mutated patients
with O/E=5.16, p=0.020. The current analysis (3 November 2026; myeloid OncoTree codes only, one
sample per patient, 222 SETBP1 patients,
72 on DDX41-covered panels) finds 2
patients with O/E=4.26, p=0.079, not significant (BH q=0.153 among the
SETBP1 partner genes, 0.649 among all DDX41 pairs). Both runs used the same >20
coding mutation cutoff. The difference comes from the cohort definition and panel
handling, not the hypermutation filter.
| Analysis | SETBP1 Patients | DDX41+SETBP1 | O/E | p-value | BH q-value |
|---|---|---|---|---|---|
| 32-gene filter | 271 | 3 | 5.16 | 0.020 | <0.05 (no exact value kept) |
| Current (myeloid OncoTree, per patient) | 72 | 2 | 4.26 | 0.079 | NS |
References
- Polprasert C, Schulze I, Sekeres MA, Makishima H, et al. Inherited and Somatic Defects in DDX41 in Myeloid Neoplasms. Cancer Cell (2015). PubMed
- Makishima H, Saiki R, Nannya Y, et al. Germ line DDX41 mutations define a unique subtype of myeloid neoplasms. Blood (2023). PubMed
- Gurnari C, Makishima H, Durmaz A, et al. DDX41-mutant myeloid neoplasms defy current prognostic schemes and require a dedicated risk scoring system. Leukemia (2026). PubMed
- Piazza R, Valletta S, Winkelmann N, et al. Recurrent SETBP1 mutations in atypical chronic myeloid leukemia. Nat Genet (2013). PubMed
- Piazza R, Magistroni V, Redaelli S, et al. SETBP1 induces transcription of a network of development genes by acting as an epigenetic hub. Nat Commun (2018). PubMed
- Makishima H, Yoshida K, Nguyen N, et al. Somatic SETBP1 mutations in myeloid malignancies. Nat Genet (2013). PubMed
- AACR Project GENIE Consortium. AACR Project GENIE: Powering Precision Medicine through an International Consortium. Cancer Discov (2017). DOI
- Makishima H, Yoshizato T, Yoshida K, et al. Dynamics of clonal evolution in myelodysplastic syndromes. Nat Genet (2017). PubMed
- Bernard E, Tuechler H, Greenberg PL, et al. Molecular International Prognostic Scoring System for Myelodysplastic Syndromes. NEJM Evid (2022). DOI